SDC1 and plasma cell myeloma: Figure 4B shows results from our CyTOF-based differential expression (pre vs. post-17-AAG treatment) analysis, revealing shifts in IRF4 and pSTAT3 as well as myeloma cell survival markers like CD138 and phosphoproteins like pRB.